R1 Therapeutics Launches with $77.5M to Develop Novel Kidney Disease Treatment
核心洞察
R1 Therapeutics (搜索) has secured $77.5 million in Series A funding to develop AP306, a novel treatment for hyperphosphatemia (搜索) in chronic kidney disease (搜索) patients requiring dialysis.
The drug targets multiple phosphate transporters (搜索) and could offer a simpler dosing regimen compared to current treatments that have remained largely unchanged for 60 years.
Phase 2b trials are planned for later this year, with results expected in 2027, following promising Phase 2 data from China showing superior phosphorus reduction.
R1 Therapeutics (搜索) has officially launched operations with $77.5 million in Series A funding and exclusive licensing rights to develop AP306, a treatment for elevated phosphate levels in chronic kidney disease (搜索) patients requiring dialysis. The Redwood City, California-based startup acquired the rights from Shanghai-based Alebund Pharmaceuticals (搜索), which had previously licensed the drug from Chugai Pharmaceutical in 2021.
Addressing an Unmet Medical Need
Hyperphosphatemia (搜索) affects patients whose chronic kidney disease (搜索) has progressed to the point of requiring dialysis, causing phosphorus levels to rise so high they can weaken bones and damage the heart. Current treatment options have seen minimal changes over the past 60 years and typically require patients to take multiple pills with food, often resulting in digestive issues.
"When we talk to practicing nephrologists and those who are providing dialysis care for patients, what they tell us they're most excited about is that the pill burden is going to be substantially lower than the requirements with traditional phosphate binders," said Krishna Polu, R1's co-founder and CEO.
Novel Mechanism of Action
AP306 represents a departure from existing therapies by targeting multiple phosphate transporters (搜索) simultaneously. While current treatments like Renvela bind to phosphate in the gut to prevent absorption, and Xphozah targets a single protein responsible for phosphate transport, AP306 works by blocking all three known active phosphate transporters in the digestive system.
This approach allows the drug to be taken as a single pill two to three times per day, potentially offering both improved efficacy and tolerability compared to existing options that require multiple pills with each meal.
Clinical Development Progress
A Phase 2 study conducted in China demonstrated AP306's potential, showing superior phosphorus reduction compared to phosphate binders after 12 weeks of treatment. The study tested a thrice-daily regimen and showed that AP306 was more effective at bringing patients into normal phosphorus ranges.
R1 plans to advance AP306 into Phase 2b trials later this year, with results anticipated in 2027. The company's primary objective is to begin mid-stage clinical trials during the first half of 2026, with results expected in the first half of the following year.
Should the trials prove successful, R1 expects to begin late-stage development by the conclusion of 2027 and will secure additional funding to support the complete program, handle regulatory filings, and prepare for market launch.
Regulatory and Commercial Strategy
CEO Polu noted that regulatory agencies have "worked hard to identify pathways for accelerated approval of drugs around surrogate endpoints," creating increased momentum in kidney treatment development that is attracting more attention from investors and pharmaceutical companies and "provides opportunities to get new medicines to patients faster."
The company plans to handle AP306 commercialization independently in the United States while pursuing partnerships for distribution in Europe, the United Kingdom, and Japan. Medicare's Transitional Drug Add-on Payment Adjustment, which provides temporary coverage for new dialysis medications while the agency gathers data for future coverage decisions, will support the treatment's commercial prospects.
Funding and Leadership
The Series A funding round was co-led by Carlyle's Abingworth (搜索), DaVita's Venture Group, and F-Prime (搜索), with additional participation from Curie.Bio, SymBiosis, and U.S. Renal Care. The current funding should support the program through mid-stage testing and initial preparations for late-stage development.
Polu previously helped form Mineralys Therapeutics, which is now publicly traded, and Renalys Pharma, which Chugai acquired last year, bringing relevant experience in kidney disease drug development to the new venture.